The relationship between fasting blood sugar and HbA1c as it pertains to medication adjustment in type 2 diabetic patients of Bungnarang Hospital, Phichit
Keywords:fasting blood sugar, HbA1c, diabetes mellitus, medication adjustment
Objectives To evaluate the relationship between fasting blood sugar (FBS) and HbA1c, to estimate the FBS cutoff point that predicts an HbA1c of 7%, and to study medication adjustment behavior based on FBS results.
Methods A retrospective cross-sectional study was conducted by reviewing patients’ medical records, including results of FBS and HbA1c measurements. Pearson’s correlation and Receiver Operating Characteristic Curves were used to determine the relationship between FBS and HbA1c. Sensitivity and specificity tables were used to identify the FBS cut-off point that would predict HbA1c of 7%.
Results Of a total of 211 patients were included in the study, 117 had FBS > 130 mg/dL of whom 17.09% had received medication adjustment. FBS was found to be correlated with HbA1c and able to predict HbA1c of 7% with statistical significance (r = 0.55, p < 0.001), (AUC = 0.68). An FBS cut-off point of 130 mg/dL had a sensitivity of 62.00% and specificity 60.66%. In patients with higher FBS values, the specificity in predicting HbA1c increased to ≥ 7%. However, the proportion of patients with glycemic control who received medication adjustment based on FBS results was low.
Conclusions A moderate correlation exists between FBS and HbA1c. Higher FBS values increase the specificity in predicting HbA1c. When a standardized HbA1c assay is not available, the FBS cutoff point of 150 mg/dL can be used as a guide to adjustment of medication to help the patient reach the treatment goals faster.
2. World Health Organization. Diabetes 2018 [updated 30 october 2018] [cited 2019 Oct 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/diabetes
3. Diabetic Association of Thailand. Prevalence of diabetes in Thai population 2014 [cited 2019 Oct 15]. Available from: https://www.dmthai.org/index.php/knowledge/the-chart/the-chart-1/550-2018-02-09-00-17-33.
4. Bureau of Non Communicable Disease. Prevalence and mortality rate of non-communicable diseases 2016-2017 [updated 19 Oct 2019; cited 2019 Oct 20]. Available from: http://www.thaincd.com/2016/mission/documents-detail.php?id=13486&tid=32&gid=1-020
5. Diabetes Association of Thailand. Clinical Practice Guideline for Diabetes 2017. 3rd ed. Pathumthani: Romyen Media; 2017. [in Thai]
6. Nathan DM, Kuenen J, Borg R, Zheng H, Schoenfeld D, Heine RJ. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473-8.
7. The Diabetes Control and Complications Trial Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes. 1995;44:968-83.
8. The Diabetes Control and Complications Trial Research Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-53.
9. Laiteerapong N, Ham SA, Gao Y, Moffet HH, Liu JY, Huang ES, et al. The Legacy Effect in Type 2 Diabetes: Impact of Early Glycemic Control on Future Complications (The Diabetes & Aging Study). Diabetes Care. 2019;42:416-26.
10. Nathan DM, Genuth S, Lachin J, Cleary P, Crofford O, Davis M, et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-86.
11. Radin MS. Pitfalls in hemoglobin A1c measurement: when results may be misleading. J Gen Intern Med. 2014;29:388-94.
12. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327-34.
13. Ollerton RL, Playle R, Ahmed K, Dunstan FD, Luzio SD, Owens DR. Day-to-day variability of fasting plasma glucose in newly diagnosed type 2 diabetic subjects. Diabetes Care. 1999; 22:394-8.
14. Petersen PH, Jorgensen LG, Brandslund I, De Fine Olivarius N, Stahl M. Consequences of bias and imprecision in measurements of glucose and hba1c for the diagnosis and prognosis of diabetes mellitus. Scand J Clin Lab Invest Suppl. 2005;240:51-60.
15. American Diabetes Association. Glycemic Targets: Standards of Medical Care in Diabetes 2020. Diabetes Care. 2020;43(Suppl 1):S66.
16. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2019 executive summary Endocr Pract. 2019; 25:69-100.
17. Health Data Center. Ministry of Public Health. Thailand. Information in response to the Service Plan for Non communicable Diseases (NCD DM, HT, CVD): health data center; [updated 5 decebber 2019] [ited 2019 december 5]. Available from: http://hdc2.cbo.moph.go.th/hdc/reports/page.php?cat_id=b2b59e64c4e6c92d4b1ec16a599d882b.
18. Feng L, Nian S, Zhao Y, Bai X, Luo F, Luo X, et al. Higher HbA1c and/or glucose levels alter the association patterns between glycated hemoglobin and fasting glucose levels. Diabetes Res Clin Pract. 2018;142:353-62.
19. Yamamoto-Honda R, Kitazato H, Hashimoto S, Takahashi Y, Yoshida Y, Hasegawa C, et al. Distribution of blood glucose and the correlation between blood glucose and hemoglobin A1c levels in diabetic outpatients. Endocr J. 2008;55:913-23.
20. Ramachandran A, Riddle MC, Kabali C, Gerstein HC, Investigators O. Relationship between A1C and fasting plasma glucose in dysglycemia or type 2 diabetes: an analysis of baseline data from the ORIGIN trial. Diabetes Care. 2012;35:749-53.
21. Karami A, Baradaran A. Comparative evaluation of three different methods for HbA1c measurement with High-performance liquid chromatography in diabetic patients. Adv Biomed Res. 2014;3:94.
22. Subcharoan U. Comparative study of HbA1c measurement using HPLC, immunoassay and affinity chromatography techniques based on hemoglobin typing. J Med Tech Assoc Thailand. 2013;41:4446-56.
23. Fan W, Zheng H, Wei N, Nathan DM. Estimating HbA1c from timed Self-Monitored Blood Glucose values. Diabetes Research and Clinical Practice. 2018;141:56-61.
24. Sikaris K. The correlation of hemoglobin A1c to blood glucose. J Diabetes Sci Technol. 2009;3:429-38.
25. Ozmen S, Cil T, Atay AE, Tuzcu AK, Bahceci M. A simple way to estimate mean plasma glucose and to identify type 2 diabetic subjects with poor glycaemic control when a standardized HbA1c assay is not available. Diabet Med. 2006;23:1151-4.
26. Mekvanich N. The relationship between fasting plasma glucose and hemoglobin A1c for creating average plasma glucose chart in diabetic patients of Pranangklao Hospital. J Med Tech Assoc Thailand. 2014;42:4975-89.
27. Ketsuwan T, Pichayapaiboon S. Correlation between HbA1C and four hours after lunch and before dinner blood sugar levelsin patients with type 2 diabetes mellitus treated with oral antidiabetic drugs. Thai Journal of Pharmacy Practice. 2016;8:261-70.
28. Jamrat C. The relationship between fasting plasma glucose and HbA1C level in type 2 diabetic patients at Nakhornnayok hospital and Ongkarak hospital. SWU J Pharm Sci. 2004;9:43-51.
29. Srisudjai N, Pichayapaiboon S. Developing and validating an equation to predict hemoglobin A1c in type 2 diabetic patients at Phanatnikhom Hospital. Thai journal of Pharmacy Practice. 2019;11:215-25. (in Thai)
30. Kongkird A, Hongard P, Trakulthong J, Kangwantrakul W, Promdee L. Estimation of fasting plasma glucose from HbA1c in diabetic patients at Srinagarind hospital, Khon Kaen University. Journal of Medical Technology and Physical Therapy. 2014;26:26-31. (in Thai)
31. Flahault A, Cadilhac M, Thomas G. Sample size calculation should be performed for design accuracy in diagnostic test studies. J Clin Epidemiol. 2005;58:859-62.
32. Karnchanasorn R, Huang J, Ou HY, Feng W, Chuang LM, Chiu KC, et al. Comparison of the current diagnostic criterion of HbA1c with fasting and 2-hour plasma glucose concentration. J Diabetes Res. 2016;2016:6195494.
33. Rangsin R. An assessment on quality of care among patients diagnosed with type 2 diabetes and hypertension visiting hospitals of Ministry of Public Health and Bangkok Metropolitan Administration in Thailand, 2012: National Health Security Office [updated May 2020; cited 2020 Dec 5]. Nov 2012:[Available from: https://www.nhso.go.th/
34. Shrestha L, Jha B, Yadav B. Correlation between fasting blood glucose, postprandial blood glucose and glycated hemoglobin in non-insulin treated type 2 diabetic subjects. Sunsari Technical College Journal 2012;1:18-21.
35. Reach G, Pechtner V, Gentilella R, Corcos A, Ceriello A. Clinical inertia and its impact on treatment intensification in people with type 2 diabetes mellitus. Diabetes Metab. 2017; 43:501-11.
36. Hsu WC. Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J. 2009;102:67-76.
37. Pholdee L, Vejakama P, Khunawaradisai N, Watcharathanakij S. Clinical Inertia in Type 2 diabetic patients in community hospitals in Ubon Ratchathani. Thai Journal Of Pharmacy Practice. 2019;12:128-39. (in Thai)
38. O’Connor PJ, Sperl-Hillen JM, Johnson PE, Rush WA, Biltz G. Clinical inertia and outpatient medical errors. Henriksen K, Battles JB, Marks ES, Lewin DI, editors. Rockville (MD): Agency for Healthcare Research and Quality (US); 2005.
39. Bralić Lang V, Bergman Marković B, Kranjčević K. Family physician clinical inertia in glycemic control among patients with type 2 diabetes. Med Sci Monit. 2015;21:403-11.